免疫球蛋白重链基因重排作为非霍奇金淋巴瘤患者的血浆生物标志物
IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients.
作者信息
He Jian, Wu Jian, Jiao Yuchen, Wagner-Johnston Nina, Ambinder Richard F, Diaz Luis A, Kinzler Kenneth W, Vogelstein Bert, Papadopoulos Nickolas
机构信息
The Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
出版信息
Oncotarget. 2011 Mar;2(3):178-85. doi: 10.18632/oncotarget.235.
New biomarkers with improved accuracy could be helpful for monitoring disease in patients with Non-Hodgkin's lymphomas (NHL). Towards this end, we have explored the feasibility of identifying the sequence of rearranged IgH genes using next-generation sequencing, then using PCR to detect specific rearranged DNA fragments in patients' plasma. By capturing and sequencing the IgH genomic regions (IgCap), we were able to detect and precisely determine the sequence of rearranged IgH loci in the tumors of three NHL patients. Moreover, circulating rearranged DNA fragments could be identified in the plasma of all three patients. Even in cases wherein tumor biopsies were unavailable, we were able to use the IgH capture approach to identify rearranged DNA loci in the plasma of 8 of 14 patients. IgCap may enable a more informed management of selected patients with NHL and other B-cell malignancies in the future.
具有更高准确性的新型生物标志物可能有助于监测非霍奇金淋巴瘤（NHL）患者的疾病情况。为此，我们探索了使用下一代测序技术鉴定重排IgH基因序列，然后利用聚合酶链反应（PCR）检测患者血浆中特定重排DNA片段的可行性。通过捕获和测序IgH基因组区域（IgCap），我们能够检测并精确确定三名NHL患者肿瘤中重排IgH基因座的序列。此外，在所有三名患者的血浆中都能鉴定出循环重排DNA片段。即使在无法获取肿瘤活检样本的情况下，我们也能够使用IgH捕获方法在14名患者中的8名患者血浆中鉴定出重排DNA基因座。未来，IgCap可能会使对部分NHL患者和其他B细胞恶性肿瘤患者的管理更加科学。
Zotero 插件